CASI Pharmaceuticals, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsCASI Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the China market, with a portfolio of in-licensed and internally developed drugs, but it is currently loss-making and has a negative shareholder equity position.
What they do
CASI Pharmaceuticals operates primarily in China, where it markets and distributes in-licensed pharmaceutical products. The company has a portfolio that includes oncology and other therapeutic areas, and it also has development-stage assets, including a cell therapy program through its investment in Juventas. Its operations are conducted through Chinese subsidiaries, including CASI Pharmaceuticals (China) Co., Ltd. and CASI Pharmaceuticals (Wuxi) Co., Ltd.
Revenue drivers
- In-licensed products in China — The company generates revenue by commercializing drugs in China; the specific products are not named in the provided excerpts, but the revenue has declined from $30.0M in 2021 to $20.7M in 2025.
- Oncology portfolio — CASI's portfolio is focused on oncology, which is a key therapeutic area for the China market, though specific product names and sales figures are not provided in the excerpts.
- Emerging cell therapy (via Juventas) — Through its equity investment in Juventas Cell Therapy Ltd., the company has exposure to cell therapy, which is a potential future revenue stream but is not yet a source of current revenue.
Recent performance
In 2025, CASI reported revenue of $20.7M, down from $28.5M in 2024 and $33.9M in 2023. The net loss widened to $48.1M in 2025 from $39.3M in 2024, while diluted EPS was -$2.59. Operating cash flow was negative at -$20.8M for 2025. As of December 31, 2025, the company had cash and equivalents of $5.6M, total assets of $25.6M, total liabilities of $62.9M, and shareholder equity of -$37.3M.
Strategy
CASI's strategy focuses on commercializing in-licensed products in China, leveraging its local infrastructure and regulatory expertise. The company is also investing in development-stage assets, including cell therapy through its investment in Juventas, to expand its pipeline. Additionally, the company has been managing its cost base, as evidenced by reduced operating cash burn in 2025 compared to 2024. The company's future direction is dependent on its ability to secure additional funding, given its negative equity position.
Risks
- Substantial doubt about going concern — The company has a negative shareholder equity of -$37.3M and only $5.6M in cash, which raises significant doubt about its ability to continue as a going concern.
- Declining revenue — Revenue has fallen from $38.0M in 2022 to $20.7M in 2025, indicating a worsening commercial performance.
- Persistent operating losses — The company has recorded net losses in every year from 2021 to 2025, with the most recent loss of $48.1M in 2025.
- Dependence on China market — The company's operations are concentrated in China, making it vulnerable to regulatory changes, pricing pressures, and other risks specific to the Chinese pharmaceutical market.
Outlook
Management's forward-looking statements indicate that the company expects to face ongoing challenges, including the need to raise capital. Given the cash position and negative equity, the company's ability to fund operations and execute its strategy is uncertain. The outlook is cautious, with a focus on managing costs and seeking new growth opportunities, but no specific financial guidance is provided in the excerpts.